MedKoo Cat#: 562001 | Name: PF-06807656
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PF-06807656 is a a potent ROMK inhibitor (Tl+ flux IC50 = 160 nM) with low HLM turnover and good passive permeability. PF-06807656 is insensitive to the introduction of the N171D mutation in the ROMK conduction pore that greatly diminishes the activity of other small-molecule inhibitors.

Chemical Structure

PF-06807656
PF-06807656
CAS#Unknown

Theoretical Analysis

MedKoo Cat#: 562001

Name: PF-06807656

CAS#: Unknown

Chemical Formula: C19H20ClN5O4S

Exact Mass: 449.0925

Molecular Weight: 449.91

Elemental Analysis: C, 50.72; H, 4.48; Cl, 7.88; N, 15.57; O, 14.22; S, 7.13

Price and Availability

Size Price Availability Quantity
5mg USD 265.00 2 Weeks
25mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PF-06807656; PF 06807656; PF06807656;
IUPAC/Chemical Name
3-(N-(4-chlorophenyl)sulfamoyl)-4-methoxy-N-(1-(2-methyl-2H-1,2,3-triazol-4-yl)ethyl)benzamide
InChi Key
DERVNKULTWJINM-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H20ClN5O4S/c1-12(16-11-21-25(2)23-16)22-19(26)13-4-9-17(29-3)18(10-13)30(27,28)24-15-7-5-14(20)6-8-15/h4-12,24H,1-3H3,(H,22,26)
SMILES Code
O=C(NC(C1=NN(C)N=C1)C)C2=CC(S(=O)(NC3=CC=C(Cl)C=C3)=O)=C(OC)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 449.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors. Matthew F. Sammons*† , Sujay V. Kharade*‡, Kevin J. Filipski† , Markus Boehm† , Aaron C. Smith§, Andre Shavnya§, Dilinie P. Fernando§⊥, Matthew S. Dowling§, Philip A. Carpino† , Neil A. Castle∥#, Shannon G. Zellmer∥#, Brett M. Antonio∥#, James R. Gosset†, Anthony Carlo§, and Jerod S. Denton‡. † Pfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States ‡ Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States § Pfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States Neusentis, Pfizer Worldwide Research & Development, Durham, North Carolina 27703, United States ACS Med. Chem. Lett., Article ASAP DOI: 10.1021/acsmedchemlett.7b00481 Publication Date (Web): January 19, 2018 Copyright © 2018 American Chemical Society Verlee, A. (2019). Innovative synthetic methods toward potential anti-oxidative stress agents for plants (Doctoral dissertation, Ghent University).